personalized medicine news from FierceBiotech
News
Invitrogen gets breast cancer test approval
Invitrogen has won FDA approval of a test that can determine whether a woman with breast cancer will benefit from Genentech's Herceptin. The SPOT-Light test, as it is known, uses a DNA probe for the... Read more...
Expert forecasts revolution in drug dev. work
In the not too distant future drug development work will be revolutionized by new computer technology that will "test" experimental therapies on virtual humans, says a new report from... Read more...
Perlegen, 454 to study drug response
Perlegen Sciences and 454 Life Sciences (now owned by Roche) have teamed up to conduct large scale genetic re-sequencing... Read more...
Genetic test seen as big step to personalized meds
A few weeks ago, the FDA roiled the scientific community with its decision... Read more...
Molecular diagnostics firm gains $34M in VC
Amsterdam-based Agendia, a molecular diagnostics company, has raised $34 million in its fourth venture round, adding ING to its list of backers. Current investors Van Herk Biotech, Gilde Healthcare... Read more...
Get more personalized medicine coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
